31,543 Shares in Pfizer, Inc. (PFE) Acquired by Crescent Grove Advisors LLC
Crescent Grove Advisors LLC acquired a new position in Pfizer, Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 31,543 shares of the biopharmaceutical company’s stock, valued at approximately $1,060,000.
Several other institutional investors have also added to or reduced their stakes in PFE. Canada Pension Plan Investment Board boosted its position in shares of Pfizer by 249.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after buying an additional 7,649,416 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Pfizer by 6.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock worth $1,117,696,000 after buying an additional 2,013,835 shares in the last quarter. Boston Partners boosted its position in shares of Pfizer by 7.3% in the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after buying an additional 1,649,801 shares in the last quarter. Sanders Capital LLC boosted its position in shares of Pfizer by 10.8% in the 2nd quarter. Sanders Capital LLC now owns 16,933,077 shares of the biopharmaceutical company’s stock worth $626,222,000 after buying an additional 1,644,036 shares in the last quarter. Finally, Bank of Nova Scotia boosted its position in shares of Pfizer by 325.9% in the 1st quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock worth $66,180,000 after buying an additional 1,480,258 shares in the last quarter. Institutional investors and hedge funds own 69.10% of the company’s stock.
Shares of Pfizer, Inc. (NYSE:PFE) opened at $35.18 on Friday. The stock has a market cap of $207,510.00, a P/E ratio of 14.14, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a 1 year low of $30.51 and a 1 year high of $36.78. The company has a current ratio of 1.34, a quick ratio of 1.06 and a debt-to-equity ratio of 0.58.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.61 EPS. analysts expect that Pfizer, Inc. will post 2.59 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.64%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.
A number of research analysts have issued reports on PFE shares. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 17th. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and upped their target price for the company from $33.00 to $37.00 in a report on Wednesday, August 2nd. UBS AG restated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a report on Monday, July 31st. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Finally, Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. Pfizer has an average rating of “Hold” and an average price target of $38.48.
In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the sale, the executive vice president now owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 374,621 shares of company stock valued at $12,796,098. Corporate insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.